Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Kerna Labs leverages advanced artificial intelligence and high-throughput biology to develop next-generation mRNA therapeutics. The company’s proprietary platform addresses key challenges in mRNA payload design, stability, expression profiles, and targeted delivery. Founded by industry veterans from Deep Genomics and Moderna—including Julia Peng (CEO) and Melissa J. Moore—the company recently raised an oversubscribed seed round to accelerate its mission of unlocking the full potential of mRNA as a universal toolkit for genetic medicine. Clinical results are not yet available as the company remains in preclinical stages but aims to enable therapies across a broad range of indications beyond infectious disease.[1][3][4]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Kerna Labs.